{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03155191",
      "OrgStudyIdInfo": {
        "OrgStudyId": "1501-01"
      },
      "Organization": {
        "OrgFullName": "Takara Bio Inc.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "OfficialTitle": "A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia",
      "Acronym": "TBI-1501"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 1, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 31, 2035",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 31, 2035",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 14, 2017",
      "StudyFirstSubmitQCDate": "May 15, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 16, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "December 24, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 28, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Takara Bio Inc.",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Otsuka Pharmaceutical Co., Ltd.",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.",
      "DetailedDescription": "Enroll patients after confirming eligibility. Following enrollment, peripheral blood mononuclear cells and blood plasma will be obtained from each subject by apheresis to start the manufacturing of TBI-1501.\n\nBefore TBI-1501 administration, it is necessary to pass the quality tests. Subject will be hospitalized from Day -3 to Day 28, and administered Cyclophosphamide (1,000 mg/m2/day×2 days) on Day -3 and Day -2."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Lymphoblastic Leukemia, Acute Adult"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Acute lymphoblastic leukemia",
          "Leukemia",
          "Lymphoblastic",
          "TBI-1501",
          "Anti-CD19 CAR Expressing T cells Therapy",
          "CD19 CAR Gene-Transduced Lymphocyte",
          "Adoptive Immunotherapy",
          "Genetically Engineered Lymphocyte Therapy",
          "Retroviral Vector",
          "Neoplasms by Histologic Type",
          "Neoplasms",
          "Neoplasms, Experimental",
          "Immune System Diseases",
          "Chimeric antigen receptor"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "Peripheral blood will be collected from a subject after obtaining a written informed consent. Peripheral blood mononuclear cells (PBMCs) and plasma are obtained from the blood, and T cells contained in the PBMCs are transduced with anti-CD19 CAR gene by using retroviral vector.\n\nCyclophosphamide will be administered after obtaining a written informed consent and completing registration.\n\nCD19-CAR-T will be administered in the split dose. Phase 2 recommended dose will be applied for phase 1 portion. The investigator assesses efficacy of CD19-CAR-T in accordance with study-specific criteria, at 8 week after the infusion of CD19-CAR-T (or at the time of termination). The investigator also assesses the safety during the follow-up period. Long-term follow-up study is conducted at frequency of once a year for 15 years after the infusion of CD19-CAR-T in reference to guidelines of FDA.",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "21",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Dose Level -1 to 2",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.\n\ncohort -1: 3×10^5 cells/kg cohort 1: 1×10^6 cells/kg cohort 2: 3×10^6 cells/kg.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: TBI-1501"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "TBI-1501",
            "InterventionDescription": "Phase-I portion:\n\nCyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10^5 cells/kg, cohort 1: 1×10^6 cells/kg, cohort 2: 3×10^6 cells/kg).\n\nPhase-II portion:\n\nRecommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Dose Level -1 to 2"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Phase-I portion: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0",
            "PrimaryOutcomeDescription": "Adverse event (frequency, seriousness, duration, causality, severity, classification), mortality, severe adverse event, discontinuation due to adverse event.",
            "PrimaryOutcomeTimeFrame": "One year"
          },
          {
            "PrimaryOutcomeMeasure": "Phase-II portion: Anti-tumor effect (CR+CRi rate)",
            "PrimaryOutcomeDescription": "Complete Remission (CR)+Complete Remission with Incomplete Blood Count Recovery (CRi) , as determined by assessments of peripheral blood and bone marrow.",
            "PrimaryOutcomeTimeFrame": "56 days"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nIn phase-1 study, patients must be ≥ 18 years of age. In phase-2 study, patients must be ≥ 16 years of age.\nPatients with relapse or refractory CD19+ acute B-cell lymphoblastic leukemia\nPatients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n\nPatients must have adequate key organ function (bone marrow, heart, lung, liver, renal, etc), as defined below\n\nTotal bilirubin level ≤1.5xULN (Upper limit of normal)\nAST(GOT)/ALT(GPT) level ≤5.0xULN\nSerum creatinine ≤2.0mg/dL\nSpO2 ≧ 92%\nLVEF ≥50%\nPatients must be able to understand and willing to sign a written informed consent document (for patients <20 years of age their legal guardian must give informed consent).\n\nExclusion Criteria:\n\nWhite blood cell counts ≧ 50,000/uL\nReceived expected antitumor therapy (chemotherapy or radiation therapy, etc) within 2 weeks.\nReceived HSCT within 12 weeks before enrollment.\nUnder treatment for GVHD.\nlymphocytes except for blasts ≦ 500/uL\nPresence of active CNS-3\nConcurrent use of systemic steroids or immunosuppressive agents (except for replacement therapy and local administration. e.g. inhalation, application and so on).\nHBs Ag positive ,or either HBc Ab positive or HBs positive with HBV-DNA > 1.3LogIU/ml\nPresence of active hepatitis C infection\nHIV Ab or anti-HTLV-1 Ab positive\nHistory of allergy about component of investigational product or animal(cattle and/or mouse)-derived additives\nHypersensitivity to antibiotics.\nPresence of symptomatic cardiac arrhythmias or serious heart disease.\nPresence of another malignant tumor.\nPsychiatric disorder, alcohol addiction or drug addiction that affects the ability of informed consent.\nActive or serious infection.\nBoth men and women who have generative functions, and who cannot agree with using contraceptive devices from the day of the consent to the end of study.\nPregnant or lactating women.\nAny other patients judged by the investigators to be inappropriate for the study.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "16 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Otsuka Pharmaceutical Co., LTD.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+81-3-6361-7314",
            "CentralContactEMail": "CL_OPCJ_RDA_Team@otsuka.jp"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University Of Fukui Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Yoshida",
            "LocationState": "Fukui",
            "LocationZip": "910-1193",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Kyushu University Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Higashi-ku",
            "LocationState": "Fukuoka",
            "LocationZip": "812-8582",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Hokkaido University Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Sapporo-shi",
            "LocationState": "Hokkaido",
            "LocationZip": "060-8648",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Kobe City Medical Center General Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Kobe",
            "LocationState": "Hyogo",
            "LocationZip": "650-0047",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Mie University Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Tsu-shi",
            "LocationState": "Mie",
            "LocationZip": "514-8507",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Tohoku University Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Sendai",
            "LocationState": "Miyagi",
            "LocationZip": "980-8574",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Jichi Medical University hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Shimotsuke-shi",
            "LocationState": "Tochigi",
            "LocationZip": "329-0498",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Cancer Institute Hospital Of JFCR",
            "LocationStatus": "Recruiting",
            "LocationCity": "Kōto",
            "LocationState": "Tokyo",
            "LocationZip": "135-8550",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "The Institute of Medical Science, The University of Tokyo",
            "LocationStatus": "Recruiting",
            "LocationCity": "Minato-ku",
            "LocationState": "Tokyo",
            "LocationZip": "108-8639",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Akita University Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Akita",
            "LocationZip": "010-8543",
            "LocationCountry": "Japan"
          },
          {
            "LocationFacility": "Okayama University Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Okayama",
            "LocationZip": "700-8558",
            "LocationCountry": "Japan"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007938",
            "ConditionMeshTerm": "Leukemia"
          },
          {
            "ConditionMeshId": "D000054198",
            "ConditionMeshTerm": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
          },
          {
            "ConditionMeshId": "D000007945",
            "ConditionMeshTerm": "Leukemia, Lymphoid"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000008232",
            "ConditionAncestorTerm": "Lymphoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000008206",
            "ConditionAncestorTerm": "Lymphatic Diseases"
          },
          {
            "ConditionAncestorId": "D000007160",
            "ConditionAncestorTerm": "Immunoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10097",
            "ConditionBrowseLeafName": "Leukemia",
            "ConditionBrowseLeafAsFound": "Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10103",
            "ConditionBrowseLeafName": "Leukemia, Lymphoid",
            "ConditionBrowseLeafAsFound": "Lymphoblastic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M26738",
            "ConditionBrowseLeafName": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "ConditionBrowseLeafAsFound": "Lymphoblastic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11471",
            "ConditionBrowseLeafName": "Neoplasms, Experimental",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10372",
            "ConditionBrowseLeafName": "Lymphoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10377",
            "ConditionBrowseLeafName": "Lymphoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10355",
            "ConditionBrowseLeafName": "Lymphatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9358",
            "ConditionBrowseLeafName": "Immunoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T175",
            "ConditionBrowseLeafName": "Acute Lymphoblastic Leukemia",
            "ConditionBrowseLeafAsFound": "Lymphoblastic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3533",
            "ConditionBrowseLeafName": "Lymphoblastic Lymphoma",
            "ConditionBrowseLeafAsFound": "Lymphoblastic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3543",
            "ConditionBrowseLeafName": "Lymphosarcoma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M5879",
            "InterventionBrowseLeafName": "Cyclophosphamide",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}